2025-12-21 - Analysis Report
Okay, here's a comprehensive analysis of UnitedHealth Group (UNH) based on the data you provided.

**1) Return Rate Comparison and Alpha/Beta Analysis**

*   **Company Overview:** UnitedHealth Group Inc. is a diversified healthcare company operating in the United States.
*   **Performance:** UNH has significantly underperformed the S&P 500 (VOO) recently. Its cumulative return is -18.40% compared to VOO's 100.88%, resulting in a divergence of -116.5 (relative divergence of 8.5). This means the recent underperformance is near the lower end of its historical range relative to the market.

*   **Alpha, Beta Analysis Table:**

    | Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
    |------------|------|------|-------|------|-------|
    | 2015-2017  | 58.0% | 66.4% | 30.0% | 0.1 | 199.7 |
    | 2016-2018  | 41.0% | 70.4% | 26.0% | 0.1 | 225.7 |
    | 2017-2019  | 36.0% | 73.8% | 14.0% | 0.2 | 266.3 |
    | 2018-2020  | -43.0% | 81.2% | -67.0% | 0.5 | 317.7 |
    | 2019-2021  | 16.0% | 81.2% | -30.0% | 1.5 | 454.9 |
    | 2020-2022  | -1.0% | 81.2% | 0.0% | 1.5 | 480.3 |
    | 2021-2023  | 24.0% | 80.8% | 23.0% | 0.4 | 476.9 |
    | 2022-2024  | -27.0% | 78.8% | -47.0% | 0.3 | 458.2 |
    | 2023-2025  | -61.0% | 79.8% | -126.0% | 1.2 | 296.6 |

    *   **Analysis:**
        *   **CAGR & MDD:** The CAGR (Compound Annual Growth Rate) has fluctuated significantly, with recent periods showing negative growth.  The MDD (Maximum Drawdown) is consistently high, indicating substantial potential for losses.
        *   **Alpha:**  Alpha, representing performance relative to the market, has been strongly negative in recent periods (2018-2020, 2019-2021, 2022-2024, 2023-2025), signifying underperformance compared to its benchmark.
        *   **Beta:** Beta, measuring volatility relative to the market, has increased in recent years, suggesting UNH is becoming more sensitive to market movements.  The large beta values in 2019-2021, 2020-2022, and 2023-2025 indicate a period of high correlation with, and potentially amplified movements compared to, the market.
        *   **Cap(B):** Market capitalization has been declining due to the recent low stock prices.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** $327.42
*   **Previous Close:** $328.14
*   **Change:** -$0.22
*   **5-day SMA:** $332.50
*   **20-day SMA:** $329.99
*   **60-day SMA:** $340.11

    *   **Analysis:** The stock price is slightly down from the previous close.  The 5-day SMA is above the 20-day SMA, but both are below the 60-day SMA. This suggests a potential short-term upward trend, but the overall trend based on the 60-day SMA is still downward.

**3) RSI, PPO, and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 52.25 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.1151 (Positive, but close to zero, suggesting limited momentum)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Dividend_2.21 (Cash Ratio: 0% on 2025-12-08) - This signal suggests a buy recommendation with a small allocation of cash, emphasizing a dividend strategy, while also saying MRI is 0.80
*   **Recent (20 days) relative divergence change:** 2.3 (+) 단기상승 (Short-term increase)
*   **Expected Return (%):** -216.9% (Significantly negative expected return compared to S&P 500.)

    *   **Analysis:** The MRI suggests a medium investment recommendation. The RSI is neutral. PPO is weakly positive. The recent short-term divergence change indicates a minor recent uptick. The extremely negative expected return is a significant red flag.

**4) Recent News & Significant Events**

*   **Key Themes:** The news headlines point to several themes:
    *   **Dividend Potential:**  Articles discuss UNH's potential as a dividend stock for 2026.
    *   **External Audits & Improvements:**  News focuses on the results of external reviews and UnitedHealth's efforts to address findings.
    *   **OptumRx Expansion:** Articles highlight the growth of UnitedHealth's OptumRx pharmacy benefit management business.
    *   **Policy Risk:** News mentions policy risk and Trump premium comments, indicating potential concerns about regulatory changes.
    *   **Wall Street Forecasts:** The news alludes to analyst opinions and forecasts for UNH.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.96)
*   **Opinions:** 25 analysts
*   **Target Price:**
    *   Average: $392.24
    *   High: $440.00
    *   Low: $280.00
*   **Analysis:**  Despite the recent underperformance, analysts generally have a "Buy" rating on the stock, with an average target price significantly above the current price.  This suggests analysts believe the stock is undervalued and has potential for future growth.

**5) Recent Earnings Analysis**

| 날짜        | EPS  | 매출         |
|-------------|------|-------------|
| 2025-10-28 | 2.59 | 113.16 B$ |
| 2025-08-11 | 3.76 | 111.62 B$ |
| 2025-05-07 | 6.9  | 109.58 B$ |
| 2024-11-04 | 6.56 | 100.82 B$ |
| 2025-10-28 | 6.56 | 100.82 B$ |

*   **Analysis:** Revenue has been steadily increasing. The Earnings per Share (EPS) has been very erratic (unstable earnings).  The recent EPS figures are quite volatile, which may be concerning to investors.

**6) Financial Information**

*Revenue and Profitability*

| Quarter      | Revenue      | Profit Margin |
|--------------|--------------|---------------|
| 2025-09-30 | $113.16B    | 18.24%        |
| 2025-06-30 | $111.62B    | 17.93%        |
| 2025-03-31 | $109.58B    | 21.70%        |
| 2024-12-31 | $100.81B    | 21.14%        |
| 2024-09-30 | $100.82B    | 22.84%        |

*Capital and Profitability:*

| Quarter      | Equity       | ROE   |
|--------------|--------------|-------|
| 2025-09-30 | $95.79B    | 2.45% |
| 2025-06-30 | $94.72B    | 3.60% |
| 2025-03-31 | $95.04B    | 6.62% |
| 2024-12-31 | $92.66B    | 5.98% |
| 2024-09-30 | $94.53B    | 6.41% |

*   **Analysis:**
    *   **Revenue:** Revenue has been consistently increasing over the reported quarters, indicating strong top-line growth.
    *   **Profit Margin:** Profit margins have fluctuated but generally remain healthy. The recent decline suggests increased costs or pricing pressures.
    *   **Equity:** Shareholder equity has shown slight increases, reflecting reinvestment of profits.
    *   **ROE:** Return on Equity (ROE) has significantly decreased in the recent quarter, potentially indicating lower profitability relative to the capital invested by shareholders.

**7) Comprehensive Analysis**

*   **Bearish Signals:**
    *   **Significant Underperformance:**  UNH has substantially underperformed the S&P 500.
    *   **Negative Alpha:**  Indicates poor risk-adjusted performance compared to its benchmark.
    *   **Decreasing CAGR:** Indicates a significant downward trend in the stock's growth rate.
    *   **High MDD:** Indicates a high level of risk and potential for large losses.
    *   **Negative Expected Return:** A significantly negative expected return suggests the stock is not expected to perform well in the future.
    *   **Volatile EPS:** The erratic nature of the EPS raises concerns about the stability of earnings.
    *   **Decreasing ROE:** Indicates a decreasing efficiency in generating profits from shareholders' equity.
*   **Bullish Signals:**
    *   **Analyst "Buy" Rating:** Despite the challenges, analysts remain optimistic about UNH.
    *   **Increasing Revenue:** Top-line growth is a positive sign.
    *   **News of Dividend Potential:** May attract income-seeking investors.
    *   **News of Audit Improvements:** Indicates the company is taking steps to improve.
*   **Mixed Signals:**
    *   **MRI:** The Medium Investment recommendation suggests the stock is not overly risky, but the Hybrid Signal's different MRI value complicates the signal's reliability.
    *   **Beta:** Higher Beta indicates more risk.
    *   **OptumRx Expansion:** A positive development, but its impact on overall profitability needs further assessment.
    *   **Policy Risk:** The news about policy risk creates uncertainty.

*   **Overall Assessment:** Based on the data provided, UNH presents a mixed picture. While analysts remain optimistic and revenue is growing, the significant underperformance, negative alpha, volatile earnings, and negative expected return are serious concerns.
*   **Recommendation:** The data suggests caution. While the analyst consensus is "Buy," a closer look at their reasoning and target price assumptions is warranted. Investors should carefully weigh the risks and potential rewards before investing in UNH. The negative expected return is a major red flag.

**Disclaimer:** This analysis is based solely on the information you provided and does not constitute financial advice. It is essential to conduct thorough research and consult with a qualified financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.